Form D · Pharmaceuticals
LA JOLLA PHARMACEUTICAL CO
San Diego, CA · CIK 0000920465
Offering snapshot reported Oct 9, 2013 · SEC filing
- Reported sold
- $17.8M Offering amount: $17.8M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 24, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 9, 2013 | Initial | $17,755,714 | No comparison | 21 | SEC filing |
| Apr 18, 2011 | Initial | $5,183,999 | No comparison | 9 | SEC filing |
| Feb 11, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 2, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-204300
RESTRICTED STOCK AWARDS
Source: Form D, filed Oct 9, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert A. Fildes | Director |
| Deirdre Y. Gillespie | Director, Executive |
| Bertrand C. Liang | Director |
| Stephen M. Martin | Director |
| James Rolke | Executive |
| Gail A. Sloan | Executive |
| Ruiz Stacey | Executive |
| George Tidmarsh | Director, Executive |
| Saiid Zarrabian | Director |
| Chester Zygmont, Iii | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4660 La Jolla Village Drive, Suite 1070
San Diego, CA, 92122
San Diego, CA, 92122